Clinical trials: Hepatic Neoplasm
Hepatic Cancer
Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis
Currently, ultrasound with or without AFP is the standard of care when it comes to surveillance for HCC in high-risk populations.
- Trial name
- Seravue (NCT06994130)
- Testing
- Seravue
- Where
- United States
- Volunteers
- 1,392 people
- Sponsor
- ImCare Biotech
Gastric Cancer, Hepatocellular Carcinoma
Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
This is a phase II, single arm, open-label study of two parallel cohorts (advanced stomach and gastroesophageal junction cancer and hepatocellular carcinoma), evaluating the effects of telatinib in combination with Keytruda on…
- Trial name
- NCT04798781
- Testing
- Telatinib, Keytruda
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Andrew Hendifar, MD
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor cells.
- Trial name
- NCT00089401
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Liver Transplantation, No-touch Technique
Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma
The "no-touch" technique has been one of the most important principles of oncological surgery and aimed to prevent seeding and tumor cell dissemination.
- Conditions
- Liver Transplantation, No-touch Technique, Hepatocellular Carcinoma
- Trial name
- NCT06331273
- Testing
- Liver transplantation with "No-touch" technique
- Volunteers
- 800 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
The purpose of this study is to evaluate the clinical efficacy of thymopentin on the prevention of the recurrence and metastasis of small HCC after resection.
- Trial name
- NCT00460681
- Testing
- Thymopentin
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Hepatitis B
Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide with an estimated 626,000 new cases per year worldwide, accounting for 5.7% of new cancer cases.
- Trial name
- NCT01018381
- Testing
- PEIT, TOCE, TOCE plus PEIT
- Where
- Vietnam
- Volunteers
- 130 people
- Sponsor
- The 108 Military Central Hospital
Liver Metastases, Liver Cancer
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
Liver resection is the treatment of choice in patients with malignant liver lesions. Unfortunately, the surgery is not always an option, as in same patients the future remnant liver (FRL) is too small to supply all the functions.
- Conditions
- Liver Metastases, Liver Cancer, Liver Neoplasms, Liver Metastasis Colon Cancer
- Trial name
- TANGO-LIVER (NCT06050200)
- Testing
- PVE, LVD, ALPPS
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Medical University of Warsaw
Hepatocellular Carcinoma (HCC)
WGc-0201 Plus Tislelizumab in HCC With High Risk of Recurrence and Metastasis After Radical Therapy
urgical treatment represents a critical approach for HCC patients to achieve long-term survival, primarily including hepatectomy and liver transplantation.
- Trial name
- NCT07077369
- Testing
- WGc-0201 injection, Tislelizumab
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Carcinoma, Hepatocellular
Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib
This study will collect data of patients who are treated with TACE followed by sorafenib for hepatocellular carcinoma (HCC) or patients without Sorafenib after TACE.
- Trial name
- OPTIMIS (NCT01933945)
- Testing
- TACE (transarterial chemoembolization), Sorafenib (Nexavar, BAY43-9006)
- Where
- 31 sites in Austria, Brazil and 29 more
- Volunteers
- 1,676 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
- Trial name
- NCT06371157
- Testing
- AK104, Lenvatinib, TACE
- Where
- 4 sites in China
- Volunteers
- 469 people
- Sponsor
- Akeso
Liver Cancer
Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
This is a phase I trial studying the side effects and best dose of stereotactic radiation therapy (SRT) in treating patients with advanced liver cancer.
- Trial name
- NCT00607828
- Testing
- stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Nebraska
Hepatocellular Carcinoma (HCC)
Can Quantitative MRI After cTACE Help Predict Survival ?
Transcatheter arterial chemoembolization (TACE) is a widely accepted palliative therapy for the treatment of HCC. Palliative means that it does not cure the disease prolongs your life and improves quality of life.
- Trial name
- NCT02173119
- Testing
- MRI post-TACE
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Medical College of Wisconsin
Carcinoma, Hepatocellular, Hepatoma
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
The main purpose of this study is to determine the safety and toxicity of treatment with SIR-Spheres® in patients with unresectable primary liver cancer or hepatocellular carcinoma (HCC).
- Trial name
- NCT00503867
- Testing
- SIR-Spheres microspheres
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sirtex Medical
Neoplasm Malignant
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment
Primary Objectives: To determine the maximum tolerated dose (MTD) and safety of Cabazitaxel when administered to advanced solid tumor patients with varying degrees of hepatic impairment To determine the pharmacokinetics (PKs) of…
- Trial name
- NCT01140607
- Testing
- Cabazitaxel (XRP6258)
- Where
- 14 sites in United States
- Volunteers
- 56 people
- Sponsor
- Sanofi
Hepatocellular Carcinoma (HCC)
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC).
- Trial name
- DARTS (NCT07027436)
- Testing
- Chemotherapy/Radiation
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Hamilton Health Sciences Corporation
Colorectal Cancer
ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis
The aim of this study is evaluate the feasibility of early two-stage hepatectomy in patients with liver metastasis from colorectal cancer.
- Trial name
- NCT01842971
- Testing
- two stage hepatectomy
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Hepatocellular Carcinoma, Liver Cirrhosis
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma (HCC)
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996.
- Conditions
- Hepatocellular Carcinoma, Liver Cirrhosis, Evidence of Liver Transplantation
- Trial name
- EFAPRE (NCT01198704)
- Testing
- search of factors predicting tumor recurrence
- Where
- France
- Volunteers
- 372 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Hepatocellular Carcinoma
Camrelizumab Utilization on Patients With Advanced Liver Cancer
To observe and evaluate the safety and efficacy of camrelizumab in advanced liver cancer
- Trial name
- NCT04487704
- Testing
- camrelizumab
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Advanced Cancer
Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients
This study is designed to evaluate the potential effect of hepatic impairment on the pharmacokinetics and safety of crizotinib in advanced cancer patients.
- Trial name
- NCT01576406
- Testing
- crizotinib
- Where
- 20 sites in United States
- Volunteers
- 88 people
- Sponsor
- Pfizer
Pancreatic Cancer, Pancreatic Adenocarcinoma
EUS-guided PORtal Vein Sampling for Circulating Tumor Cells in Pancreatic Cancer Patients
The study aims at evaluating the feasibility and safety of EUS-guided Portal Circulation sampling for isolation, enumeration and profiling od Circulating Tumor Cells (CTC) in Pancreatic Cancer patients.
- Trial name
- EUPhORIC (NCT05247164)
- Testing
- EUS-guided Portal Vein sampling
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- IRCCS San Raffaele
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.